CN1534023A - 作为多巴胺-d3配位体的杂环化合物 - Google Patents
作为多巴胺-d3配位体的杂环化合物 Download PDFInfo
- Publication number
- CN1534023A CN1534023A CNA2003101131172A CN200310113117A CN1534023A CN 1534023 A CN1534023 A CN 1534023A CN A2003101131172 A CNA2003101131172 A CN A2003101131172A CN 200310113117 A CN200310113117 A CN 200310113117A CN 1534023 A CN1534023 A CN 1534023A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- group
- formula
- het
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 37
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical class 0.000 claims description 18
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 229960003638 dopamine Drugs 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 125000000623 heterocyclic group Chemical group 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- 239000002464 receptor antagonist Substances 0.000 claims description 3
- 229940044551 receptor antagonist Drugs 0.000 claims description 3
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 102000004073 Dopamine D3 Receptors Human genes 0.000 abstract 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 19
- 239000000370 acceptor Substances 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 125000001118 alkylidene group Chemical group 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001537 neural effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- CTENFNNZBMHDDG-UHFFFAOYSA-N Dopamine hydrochloride Chemical group Cl.NCCC1=CC=C(O)C(O)=C1 CTENFNNZBMHDDG-UHFFFAOYSA-N 0.000 description 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000000994 depressogenic effect Effects 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- -1 pyrazole compound Chemical class 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 239000007940 sugar coated tablet Substances 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000015554 Dopamine receptor Human genes 0.000 description 2
- 108050004812 Dopamine receptor Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000008199 coating composition Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 150000004693 imidazolium salts Chemical class 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- WHMDPDGBKYUEMW-UHFFFAOYSA-N pyridine-2-thiol Chemical compound SC1=CC=CC=N1 WHMDPDGBKYUEMW-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NRQHBNNTBIDSRK-YRNVUSSQSA-N (4e)-4-[(4-methoxyphenyl)methylidene]-2-methyl-1,3-oxazol-5-one Chemical compound C1=CC(OC)=CC=C1\C=C\1C(=O)OC(C)=N/1 NRQHBNNTBIDSRK-YRNVUSSQSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical group C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- KKIMDKMETPPURN-UHFFFAOYSA-N 1-(3-(trifluoromethyl)phenyl)piperazine Chemical compound FC(F)(F)C1=CC=CC(N2CCNCC2)=C1 KKIMDKMETPPURN-UHFFFAOYSA-N 0.000 description 1
- GYTNHXJUEGTRJD-UHFFFAOYSA-N 1-(trifluoromethyl)piperazine Chemical compound FC(F)(F)N1CCNCC1 GYTNHXJUEGTRJD-UHFFFAOYSA-N 0.000 description 1
- VNHWPVLQRKKKRY-UHFFFAOYSA-N 1-bromo-3-fluoropropane Chemical compound FCCCBr VNHWPVLQRKKKRY-UHFFFAOYSA-N 0.000 description 1
- PHHNNDKXQVKJEP-UHFFFAOYSA-N 1-bromo-5-chloropentane Chemical compound ClCCCCCBr PHHNNDKXQVKJEP-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BPSNETAIJADFTO-UHFFFAOYSA-N 2-pyridinylacetic acid Chemical compound OC(=O)CC1=CC=CC=N1 BPSNETAIJADFTO-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013980 Dyssomnias Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N Picolinic acid Natural products OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002908 adrenolytic effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- OBISXEJSEGNNKL-UHFFFAOYSA-N dinitrogen-n-sulfide Chemical compound [N-]=[N+]=S OBISXEJSEGNNKL-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000012204 lemonade/lime carbonate Nutrition 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FNXKBSAUKFCXIK-UHFFFAOYSA-M sodium;hydrogen carbonate;8-hydroxy-7-iodoquinoline-5-sulfonic acid Chemical class [Na+].OC([O-])=O.C1=CN=C2C(O)=C(I)C=C(S(O)(=O)=O)C2=C1 FNXKBSAUKFCXIK-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 1
- 229950001675 spiperone Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Abstract
本发明涉及下式的杂环化合物:Het-A-B-Ar其中Het,A,B和Ar具有如说明书中所述的意义。根据本发明的化合物对多巴胺D3受体具有高亲和性,因而可被用于治疗响应多巴胺D3配位体的病症。
Description
本发明是申请号为95194149.6、申请日为1995年7月14日、发明名称为“杂环化合物作为多巴胺-D3配位体的用途”的中国专利申请的分案申请。
技术领域
本发明涉及杂环化合物及其用途。所说的化合物具有有价值的治疗性质,并可被用于治疗响应多巴胺D3受体配位体的病症。
背景技术
所讨论的并具有生理活性的这类化合物已被公开。US-A-4404382描述了具有抗变应性活性的相应咪唑化合物。
US-A-3362956类似地描述了此类咪唑化合物。后者具有抗肾上腺素作用和抗惊厥活性。
DE-A-2258033描述了具有中枢抑制活性的吡唑化合物。
DE-A-2717415描述了可被用于治疗过敏症的呋喃,噻吩,唑化合物。
神经无特别通过G蛋白质-偶合的受体获得其信息。有大量的物质通过这些受体发挥其作用。它们中的一个是多巴胺。
已有多巴胺存在和其作为神经递质的生理功能的确凿证据。响应多巴胺的细胞被包括在精神分裂症和帕金林病的病因学中。这些和其它病症用与多巴胺受体互相作用的药物治疗。
1990年,两个亚类的多巴胺受体已被清楚地从药理上确定,即D1和D2受体。
Sokoloff等人,在自然杂志(Nature)1990,347:164-151,发现了第三个亚类,即D3受体。它们主要在肢系统中表达。D3受体在大约一半的氨基酸残基在结构上与D1和D2受体不同。
神经抑制药的作用一般被归因于其对D2受体的亲合性。最近的受体-连接研究已确证了这一点。这显示出大多数多巴胺拮抗剂,如神经抑制药,对D2受体具有高亲合性,但对D3受体只有低亲合性。
上述现有技术化合物是这类D2受体激动剂和拮抗剂。
现已惊奇地发现,根据本发明的化合物对多巴胺D3受体具有高亲合性,对D2受体只有低亲合性。因此它们是选择性的D3配位体。
发明内容
因此,本发明涉及式I化合物和其与生理耐受酸所成的盐的用途:
Het-A-B-Ar (I)
其中
A是直链或支链C1-C18亚烷基,它可包含至少一个选自O,S,NR4,CONR4,NR4CO,COO,OCO和双键或叁键的基团
B是下式基团:
Ar是苯基,吡啶基,嘧啶基或三嗪基,其中Ar具有一至四个取代基,这些取代基各自独立地选自OR4,C1-C8基,C2-C8烯基,C2-C8炔基,卤素,CN,CO2R4,NO2,SO2R4,SO3R4,NR4R5,SO2NR4R5,SR4,CF3,CHF2,5-或6-员碳环族芳香环或非芳香环,和具有1至3个选自O,S和N的杂原子的5-或6-员杂环族芳香或非芳香环,其中这些环可以未取代或被C1-C8烷基,Hal,OC1-C8烷基,OH,NO2,CF3取代,并且其中Ar也可以与上面定义的碳环或杂环稠合。
Het是选自如下的基团
其中
R1,R2和R3互相独立地为H,卤素,OR5,
NR4R5,SR4,CF3,CN,CO2R4或未取代的或被OH,OC1-C8烷基或卤素取代的C1-C8烷基,
R4是H,或未取代的或被OH,OC1-C8烷基或卤素取代的C1-C8烷基;
R5具有对R4指明的意义,或为COR4或CO2R4;
R8具有对R5指明的意义,
用于生产治疗响应多巴胺D3受体拮抗剂或激动剂的病症的药物组合物。
根据本发明的化合物是区域选择地干扰肢系统的选择性多巴胺D3受体的配位体。因为其对D2受体的低亲合性,所以它们与作为D2拮抗剂的经典神经抑制药具有更少的副作用。因此该化合物可被用于治疗响应多巴胺D3受体拮抗剂或激动剂的病症,例如治疗中枢神经系统的病症,尤其是精神分裂,抑郁,神经机能病和精神病。它们可额外地用于治疗睡眠失调和恶心并用于抗组胺。
为本发明的目的,下列术语具有如下指明的意义:
烷基(也包括在基团如烷氧基,烷基氨基等中的那些)意指具有1至8个碳原子、优选地1至6个碳原子、尤其是1至4个碳原子的直链或支链烷基。烷基也可以含有互相独立地选自OH和OC1-C8烷基的一个或多个取代基。
烷基的例子有甲基,乙基,正丙基,异丙基,正丁基,异丁基,叔丁基,等等。
亚烷基代表具有优选2至10个碳原子、特别优选3至8个碳原子、尤其是3至6个碳原子的直链或支链基团。
亚烷基可含有至少一个上述基团。这可以-正如提到的双键或叁键-被安排在亚烷基链的任何位置或在链的终端,使其将链与杂环基相连。后者是优选的。当亚烷基包含双键或叁键时,在链中具有至少三个碳原子。
卤素是F,Cl,Br,I,尤其是Cl,Br,I。
基团Ar可具有一,二,三或四个取代基。取代基可在苯环的任何位置。然而,优选地,至少一个在间位。
优选地,它们互相独立地选自H,C1-C8烷基,OC1-C8烷基,CHF2,CF3,CN,卤素,SO2OR4和CO2R4。
Ar优选地具有至少一个取代基,尤其是
其中D1,D2和D3互相独立地为CH或N,而X和Y具有前面或下面指明的意义。
D1,D2和D3优选地为CH,或D1为N而D2和D3为CH。当基团Ar的一个取代基是5-或6-员杂环时,其例子有吡咯烷,哌啶,吗啉,哌嗪,吡啶,嘧啶,三嗪,吡咯,噻吩,噻唑,咪唑,噁唑,异噁唑,吡唑或噻二唑残基。
当基团Ar的一个取代基是碳环基时,它特别是苯基,环戊基或环己基。
当基团Ar的一个取代基是C1-C8烷基时,支链基团、尤其是异丙基或叔丁基是优选的。
当Ar与碳环或杂环稠合时,Ar尤其是萘,二-或四氢萘,喹啉,二-或四氢喹啉,吲哚,二氢吲哚,苯并咪唑,苯并噻唑,苯并噻二唑,苯并吡咯或苯并三唑残基。
优选的方案包含这样的式I化合物,其中A为包含氧或硫原子或基团CONR4、尤其是O或S的C1-C8亚烷基。
另一优选的方案包含这样的式I化合物,其中Het是如下通式:
另一优选的方案包含其中Het是下列通式的式I化合物:
另一优选的方案包含其中Het是如下通式的式I化合物:
其中,R1,R2,R3和R8总是具有前面指明的意义。
R1,R2和R3优选地相互独立地为H,NR4R5,OR5,C1-C8烷基,CO2R4,CF3或卤素。
Het其优选地具有一或两个、尤其是一个取代基。
当Het为吡啶残基时,R1,R2和R3优选地独立地选自H,卤素,OR5,NR4R5,CF3,CO2R4和C1-C8烷基。
当Het是噻吩残基时,R1和R2优选地独立地选自卤素和C1-C8烷基。
当Het是嘌呤残基时,A优选地为S-C4-C7烷基。
在另一方案中,A是可包含S,O或CONR4的C3-C6亚烷基。
X优选地为H,CF3,CN,卤素,NO2,CHF2,C1-C8烷基、尤其是C2-C4烷基,SO2R4或CO2R4,特别是H「CF3,卤素,CHF2,C1-C8烷基或CN。X特别优选地是CF3,CHF2或C2-C4烷基。
Y优选地为C1-C8烷基,尤其是C2-C4烷基,或氢。
一个特别优选的方案包含式Ia化合物:
而且特别是式Ib化合物:
其中A,Het,X和Y具有前面指明的意义。在式Ia和Ib中,尤其是X为CF3而Y为H,或X和Y都为C1-C8烷基。
本发明也包括式I化合物与生理上耐受的酸的酸加成盐。合适的生理上耐受的有机和无机酸的例子有盐酸,氢溴酸,磷酸,硫酸,草酸,马来酸,富马酸,乳酸,酒石酸,己二酸或苯甲酸。其它可被使用的酸描述于药剂研究进展,卷10,224页往后,Birkhauser出版社、巴塞尔和斯图加特,1966中。
式I化合物可具有一个或多个不对称中心。因而本发明不仅包括外消体,而且也包括相关的对映异构体的非对映异构体。本发明在各种情况下也包括互变异构形式。
那些新的式I化合物可以与开始提出的现有技术相似的方法,用熟练的技术人员熟悉的方法制备。
为了治疗上述病症,根据本发明的化合物以常规方式口服或非肠胃(皮下,静脉内,肌内,腹膜内)给药。给药也可用烟雾或喷雾通过鼻咽道进行。
剂量取决于患者的年龄,状况和体重以及给药的方式。作为规律,活性物质的日剂量为约每位患者每天口服给药约10至1000mg,每位患者每天非肠胃给药约1至500mg。
本发明也涉及含有根据本发明的化合物的药物组合物。这些组合物为常规固体或液体药物给药形式,例如片剂,包膜片剂,胶囊,粉剂,丸剂,糖衣片剂,栓剂,溶液或喷雾剂。活性物质在这些情况下可被与常规药用佐剂如片剂粘合剂,填料,防腐剂,塑化剂,湿润剂,分散剂,乳化剂,溶剂,缓释剂,抗氧化剂和/或推进气体(见H.Sucker et al.,药剂工艺(Pharmazeutische Technologie),Thieml出版社,斯图加特,1978)。以此方式获得的给药形式正常地地含有1至99%重的活性物质。
具体实施方式
下列实施例用于解释本发明,但不限制它。
实施例1
2-〔3-(4-{3-三氟甲基苯基}哌嗪基)丙硫基〕吡啶
a)1-(3-氯丙基)-4-(3-三氟甲基苯基)哌嗪
30g(0.13mol)三氟甲基苯基哌嗪,23g(0.146mol)1-溴-3-氟丙烷和15g(0.148mol)三乙胺在200ml THF中回流4小时。冷却后抽滤并浓缩。粘性的剩余物被溶于乙酸乙酯中,用水洗,MgSO4干燥然后浓缩。产生的残余物包含39g黄色油状产物(定量)
b)2-〔3-(4-{三氟甲基苯基}哌嗪基)丙硫基〕吡啶
1.11g(10mmol)2-巯基吡啶,3.1g(10.1mmol)1-(3-氯丙基)-4-(3-三氟甲基苯基)哌嗪和1.5g(15mmol)三乙胺在5ml DMF中于100℃搅拌1小时。然后将混合物倒入5%盐酸中,并用乙酸乙酯萃取。水相用氢氧化钠调成碱性,再用乙酸乙酯萃取,有机相用MgSO4干燥并浓缩。剩余物通过色谱(流动相:CH2Cl2/CH3OH=98/2)纯化。得到2.5g产物黄色油状物(=65%产率)。
H-NMR[δ,ppm]:1.95(2H);2.55(2H);2.62(4H);3.23
(6H);6.95(1H);7.05(3H);7.17(1H);7.36(1H);7.48
(1H);8.42(1H)
实施例2
2-〔5-(4-{3-三氟甲基苯基}哌嗪基)戊基巯基〕吡啶
a)2-(5-氯戊基巯基)吡啶
2.78(25mmol)2-巯基吡啶,4.64g(25mmol)1-溴-5-氯戊烷和2.58g(25.5mmol)三乙胺在100ml THF中回流4小时。冷却后抽滤,浓缩并用色谱(流动相:环己烷/乙酸乙酯=92/8)纯化剩余物。得到4g产物(=74%产率)。
b)2-〔5-(4-{3-三氟甲基苯基}哌嗪基)戊基巯基〕吡啶
2.37g(11mol)2-(5-氯戊基巯基)吡啶,2.78g(12mmol)间三氟甲基苯基哌嗪和1.22g(12.1mmol)三乙胺在5ml DMF中、在90℃搅拌5小时。然后将混合物倒入水中,并用CH2Cl2萃取三次,接着用MgSO4干燥并浓缩。剩余物与甲基叔丁基醚混合并抽滤,母液被浓缩。色谱(流动相:CH2Cl2/CH3OH=96/4)纯化产生3.0g油状产物(=67%产率)。
H=NMR[δ;ppm]:1.5(4H);1.75(2H);2.4(2H);2.6
(4H);3.2(2H);3.25(4H);7.0(1H);7.1(3H);7.2(1H);
7.35(1H);7.45(1H);8.4(1H)
实施例3
3-〔3-(4-{3-三氟甲基苯基}哌嗪基)丙基氨基羰基〕噻吩
0.76g(5.9mmol)3-噻吩羧酸,1.0g(6.2mmol)羰基二咪唑和1刮勺尖CH2Cl2中的二甲基氨基吡啶的混合物在室温搅拌1/2小时。将1.9g(5.9mmol)N-(3-三氟甲基苯基)-N’-(3-氨基丙基)哌嗪被滴加到此混合物中,将其在室温再搅拌过夜。水处理后接着SiO2层析(流动相:CH2Cl2/CH3OH=10∶1)。产生的油状物被溶于少量CH3OH中。加入0.64g(5.5mmol)在CH2Cl2中的富马酸,产生1.3g白色固体产物。熔点:124-125℃。
实施例4
2-〔2-(4-{3-三氟甲基苯基}哌嗪基)乙基氨基羰基〕吡啶
在0℃,将0.74ml甲酸氯代乙基酯滴加到0.95g 2-吡啶羧酸和1.1ml NEt3的CH2Cl2溶液中。室温搅拌15分钟后,混合物再冷却并滴加2g N-(3-三氟甲基苯基)-N’-(2-氨基乙基)哌嗪。混合物然后在室温搅拌3小时,用H2O,NH4Cl溶液,NaOH和H2O洗涤,MgSO4干燥并浓缩。从乙酸乙酯/庚烷重结晶产生1.9g产物。熔点:108-110℃。
实施例5
2-〔3-(4-{3-三氟甲基苯基}哌嗪基)丙基氨基羰基甲基〕吡啶
2.87g N-(3-三氟甲基苯基)-N’-(3-氨基丙基)哌嗪在冷却下被滴加到2.34g 2-吡啶乙酸N-羟基丁二酰亚胺酸的CH2Cl2溶液中。混合物在室温搅拌过夜,随后用NaHCO3溶液和水洗涤。有机相被分出,并用MgSO4干燥,蒸除溶剂。少量CH3OH被加入剩余物中,然后滴加乙醚中的HCl。得到2.0g白色固体产物。熔点:178-179℃。
下列化合物以类似方法合成
药物剂型实施例
A)片剂
下列组合物的片剂以常规方法在压片机上压制:
40mg 实施例1的物质
120mg 玉米淀粉
13.5mg 明胶
45mg 乳糖
2.25mg Aerosil(以亚显微细分散态的化学纯二氧化硅)
6.75mg 马铃薯淀粉(为6%的膏)
B)糖衣片剂
20mg 实施例4的物质
60mg 片芯组合物
70mg 糖衣组合物
片芯组合物包含9份玉米淀粉,3份乳糖和1份乙烯基吡咯烷酮、乙酸乙烯基酯60∶40共聚物。糖衣组合物包含5份蔗糖,2份淀粉,2份碳酸钙和1份滑石。以此方式生产的糖衣片剂随后配上肠衣。
生物学研究
受体-结合研究
从国际生物制剂保藏机构(Res.Biochemicals Internat.OneStrathmore Rd.Natick,MA01760-2148USA)得到的、经克隆的表达人D3受体的CCL1.3小鼠成纤维细胞被用于结合研究。
细胞制备
D3-表达细胞在含10%胎牛血清100U/ml青霉素和0.2%链霉素(GIBCO BRL,Gaithersburg,MD,USA)的RPMI-1640(GIBCO No.041-3240ON)中生长。48小时后,细胞用PBS洗涤,并与含0.05%胰蛋白酶的PBS一起保温5分钟,然后进行与培养基的中和作用,通过在300xg下离心,以收集细胞,为了裂解细胞,先简单地用裂解缓冲液(5mM Tris-HCl、pH7.4、含10%甘油)洗涤沉淀物,然后于4℃下、在浓度为107细胞/ml的裂解缓冲液中保温30分钟。以200xg离心细胞10分钟,将沉淀物贮存于液氮中。
结合试验
为了进行D3受体-结合试验,将膜悬浮于保温缓冲液(50mMTris-HCl、pH7.4,含120mM NaCl、5mM KCl、2mMCaCl2、2mM MgCl2、10μm羟基喹啉,0.1%抗坏血酸和0.1%BSA)中,而浓度约为106细胞/250μl试验混合物,于30℃、存在和不存在试验物质的情况下,与0.1nM125I-止呕灵一起保温,使用10-6M螺旋哌丁苯测定非特异性结合。
60分钟后,通过用Skatron细胞收集器(Skatron、Lier、Norway)上的GF/B玻璃纤维滤器(Whatman、England)过滤,以分离游离和结合的放射性配体,用冰冷的TriS-HCl缓冲液,pH7.4洗涤滤器,使用Packard 2200 CA液体闪烁计数仪定量测定滤器上收集到的放射性。
通过使用LIGAND程序的非线性回归分析测定Ki值。在此试验中,根据本发明的化合物对D3受体显示出很高的亲和力,对D2受体显示出良好的选择性。
Claims (12)
1.式I化合物和其与生理耐受酸所成盐:
Het-A-B-Ar (I)
其中
A是直链或支链C3-C8亚烷基,它可包含至少一个选自O,S,NR4,CONR4,NR4CO,COO,OCO和双键或叁键的基团
B是下式的基团:
Ar是苯基,吡啶基,嘧啶基或三嗪基,其中Ar具有一至四个取代基,这些取代基各自独立地选自OR4,C1-C8烷基,C2-C8烯基,C2-C8炔基,卤素,CN,CO2R4,NO2,SO2R4,SO3R4,NR4R5,SO2NR4R5,SR4,CF3,CHF2,5-或6-员碳环族芳香环或非芳香环,和具有1至3个选自O,S和N的杂原子的5-或6-员杂环族芳香或非芳香环,其中环可以未取代或被C1-C8烷基,Hal,OC1-C8烷基,OH,NO2,CF3取代,并且Ar也可以与上面定义的类型的碳环或杂环稠合,
Het是选自如下的基团
其中
R1,R2和R3互相独立地为H,卤素,OR5,NR4R5,SR4,CF3,CN,CO2R4,或未取代的或被OH,OC1-C8烷基或卤素取代的C1-C8烷基,
R4是H,或未取代的或被OH,OC1-C8烷基或卤素取代的C1-C8烷基;
R5具有对R4指明的意义,或为COR4或CO2R4;
R8具有对R5指明的意义。
2.如权利要求1中的式I化合物:其中
Het是如下通式的基团:
3.如权利要求2中的式I化合物:其中
Het是如下通式的基团:
5.如前面任一权利要求中式I的化合物,
其中
A是可包含O,S或CONR4的C1-C8亚烷基,
Ar是苯基或吡啶基,它可具有一个或两个互相独立地选自H,C1-C8烷基,OC1-C8烷基,CHF2,CF3,CN,卤素,SO2OR4和CO2R4的取代基,其中R4具有权利要求1中指明的意义。
6.如权利要求5中的式I化合物,
其中
A是可含有S,O或CONR4的C3-C6亚烷基,
Ar可具有一个或两个互相独立地选自H,CF3,卤素,C1-C8烷基,OC1-C8烷基和CN的取代基
B是
7.如权利要求6中的式I化合物,
其中
R1,R2和R3各自互相独立地为H,NR4R5,OR5,C1-C8烷基,CO2R4,CF3或卤素,
R4是H或C1-C8烷基,
R5是H,C1-C8烷基或CO-C1-C8烷基,而
R8是H或C1-C8烷基。
10.如权利要求9中的式Ib化合物:
其中
Het,A,X和Y具有权利要求9中所述的意义。
11.如权利要求9或10中的化合物,其中Y是H或C1-C4烷基,而X是CF3,CHF2,CN,C1-C4烷基。
12.如权利要求1至11任一项定义的化合物用于制备治疗响应多巴胺D3受体拮抗剂或激动剂的病症的药物的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4425146.7 | 1994-07-15 | ||
DE4425146A DE4425146A1 (de) | 1994-07-15 | 1994-07-15 | Verwendung heterocyclischer Verbindungen |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95194149A Division CN1152870A (zh) | 1994-07-15 | 1995-07-14 | 杂环化合物作为多巴胺d3配位体的用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1534023A true CN1534023A (zh) | 2004-10-06 |
Family
ID=6523325
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95194149A Pending CN1152870A (zh) | 1994-07-15 | 1995-07-14 | 杂环化合物作为多巴胺d3配位体的用途 |
CNA2003101131172A Pending CN1534023A (zh) | 1994-07-15 | 1995-07-14 | 作为多巴胺-d3配位体的杂环化合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN95194149A Pending CN1152870A (zh) | 1994-07-15 | 1995-07-14 | 杂环化合物作为多巴胺d3配位体的用途 |
Country Status (22)
Country | Link |
---|---|
US (1) | US6090807A (zh) |
EP (1) | EP0771197B1 (zh) |
JP (1) | JPH10502658A (zh) |
KR (2) | KR970704435A (zh) |
CN (2) | CN1152870A (zh) |
AT (1) | ATE236629T1 (zh) |
AU (1) | AU704839B2 (zh) |
BG (1) | BG63487B1 (zh) |
BR (1) | BR9508296A (zh) |
CA (1) | CA2195242A1 (zh) |
CZ (1) | CZ293126B6 (zh) |
DE (2) | DE4425146A1 (zh) |
DK (1) | DK0771197T3 (zh) |
ES (1) | ES2196072T3 (zh) |
FI (1) | FI970148A (zh) |
HU (1) | HUT77608A (zh) |
MX (1) | MX9700430A (zh) |
NO (1) | NO311683B1 (zh) |
NZ (1) | NZ290388A (zh) |
PT (1) | PT771197E (zh) |
SI (1) | SI9520084B (zh) |
WO (1) | WO1996002246A1 (zh) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6114334A (en) * | 1995-07-13 | 2000-09-05 | Knoll Aktiengesellschaft | Piperazine derivatives as therapeutic agents |
DE19600934A1 (de) | 1996-01-12 | 1997-07-17 | Basf Ag | Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung |
CZ363298A3 (cs) * | 1996-05-11 | 1999-06-16 | Smithkline Beecham P. L. C. | Tetrahydroizochinolinové deriváty jako modulátory receptorů dopaminu D3 |
AU4204697A (en) * | 1996-08-14 | 1998-03-06 | Smithkline Beecham Plc | Tetrahydroisoquinoline derivatives and their pharmaceutical use |
GB9708694D0 (en) * | 1997-04-30 | 1997-06-18 | Smithkline Beecham Plc | Compounds |
GB9708805D0 (en) * | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
GB9709303D0 (en) * | 1997-05-09 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
DE19728996A1 (de) * | 1997-07-07 | 1999-01-14 | Basf Ag | Triazolverbindungen und deren Verwendung |
TW530054B (en) * | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
US6218396B1 (en) * | 1998-02-20 | 2001-04-17 | Orth-Mcneil Pharmaceutical, Inc. | Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia |
GB9810876D0 (en) * | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
CO5140073A1 (es) | 1998-10-08 | 2002-03-22 | Smithkline Beecham Plc | Derivados de 2,3,4,5-tetrahidro-1h-3-benzapina |
DE60039377D1 (de) | 1999-02-09 | 2008-08-21 | Pfizer Prod Inc | Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit |
USRE39921E1 (en) | 1999-10-07 | 2007-11-13 | Smithkline Beecham Corporation | Chemical compounds |
GB9923748D0 (en) | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
IT1314191B1 (it) * | 1999-10-18 | 2002-12-06 | Recordati Chem Pharm | Derivati isossazolcarbossamidici |
US6365591B1 (en) | 1999-10-18 | 2002-04-02 | Recordati, S.A., Chemical And Pharmacueticals Company | Isoxazolecarboxamide derivatives |
ATE402704T1 (de) * | 2000-03-27 | 2008-08-15 | Abbott Gmbh & Co Kg | Dopamin-d3-rezeptor-liganden zur behandlung von sucht |
GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
GB0117577D0 (en) * | 2001-02-16 | 2001-09-12 | Aventis Pharm Prod Inc | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands |
GB0108594D0 (en) * | 2001-04-05 | 2001-05-23 | Glaxo Group Ltd | Chemical compounds |
HUP0103987A3 (en) * | 2001-09-28 | 2004-11-29 | Richter Gedeon Vegyeszet | Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates |
GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
EP1472222A1 (en) * | 2002-02-08 | 2004-11-03 | Glaxo Group Limited | Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases |
DE10232020A1 (de) * | 2002-07-04 | 2004-02-26 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Neurorezeptoraktive Heteroarencarboxamide |
RU2320656C2 (ru) * | 2002-07-04 | 2008-03-27 | Шварц Фарма Аг | Производные гетероаренкарбоксамида, способ их получения, фармацевтическая композиция на их основе и применение |
TW200507841A (en) * | 2003-03-27 | 2005-03-01 | Glaxo Group Ltd | Antibacterial agents |
DE10315569A1 (de) * | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituierte Pyrazolverbindungen |
US7320979B2 (en) * | 2003-04-14 | 2008-01-22 | Abbott Gmbh & Co. Kg. | N-[(piperazinyl)hetaryl]arylsulfonamide compounds |
US20040204422A1 (en) * | 2003-04-14 | 2004-10-14 | Abbott Gmbh & Co. Kg. | N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
DE10358004A1 (de) | 2003-12-11 | 2005-07-14 | Abbott Gmbh & Co. Kg | Ketolactam-Verbindungen und ihre Verwendung |
CA2550053C (en) | 2003-12-18 | 2013-01-22 | Abbott Gmbh & Co. Kg | Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor |
US20050137186A1 (en) | 2003-12-18 | 2005-06-23 | Abbott Gmbh & Co. Kg. | Tetrahydrobenzazepines and their use |
DE102004027358A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyrimidinverbindungen und ihre Verwendung |
DE102004027359A1 (de) | 2004-06-04 | 2005-12-29 | Abbott Gmbh & Co. Kg | Pyridin-2-onverbindungen und deren Verwendung |
ATE452134T1 (de) | 2004-08-09 | 2010-01-15 | Abbott Gmbh & Co Kg | Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen |
NZ555491A (en) * | 2005-01-03 | 2010-01-29 | Univ Siena | Aryl piperazine derivatives for the treatment of neuropsychiatric disorders |
JP2008528604A (ja) * | 2005-01-25 | 2008-07-31 | グラクソ グループ リミテッド | 抗菌剤 |
PA8802101A1 (es) | 2007-11-02 | 2009-08-26 | Abbott Gmbh & Co Kg | Compuestos de 1,2,4-3,5-diona adecuados para el tratamiento de trastornos que responden a la modulación del receptor de dopamina d3 |
EP2238125A1 (en) * | 2008-02-01 | 2010-10-13 | NeuroSearch A/S | Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors |
CN102264733B (zh) * | 2008-10-10 | 2014-07-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 新型多巴胺d3受体配体,其制备方法及其医药用途 |
US9227944B2 (en) | 2008-10-10 | 2016-01-05 | Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China | Dopamine D3 receptor ligands and preparation and medical uses of the same |
EP2641906B1 (en) | 2009-07-08 | 2015-04-22 | Dermira (Canada), Inc. | Tofa analogs useful in treating dermatological disorders or conditions |
WO2012027495A1 (en) | 2010-08-27 | 2012-03-01 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
US20130289047A1 (en) * | 2010-10-14 | 2013-10-31 | Epiomed Therapeutics, Inc. | Heteroarylthio derivatives and analogues |
US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
CN102408397B (zh) | 2011-10-19 | 2014-08-20 | 上海贝美医药科技有限公司 | 紫杉烷类衍生物及其制备方法 |
WO2023144764A1 (en) | 2022-01-29 | 2023-08-03 | Suven Life Sciences Limited | Benzoisothiazole and benzoisoxazole compounds for the treatment of mental disorders |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3362956A (en) * | 1965-08-19 | 1968-01-09 | Sterling Drug Inc | 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines |
DE1620016C3 (de) * | 1966-07-02 | 1979-08-30 | Merck Patent Gmbh, 6100 Darmstadt | 3-{Piperazinoalkyl)-pyrazole und Verfahren zu ihrer Herstellung |
DE2060816C3 (de) * | 1970-12-10 | 1980-09-04 | Merck Patent Gmbh, 6100 Darmstadt | 4-Phenylpiperidinderivate Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen enthaltend diese Verbindungen |
DE2110568A1 (de) * | 1971-03-05 | 1972-09-07 | Merck Patent Gmbh | Neue N-Acyl-(piperazinoalkyl)-pyrazole |
DE2213808A1 (de) * | 1972-03-22 | 1973-09-27 | Merck Patent Gmbh | Verfahren zur herstellung von 3-(piperazinoalkyl)-pyrazolen |
DE2258033A1 (de) * | 1972-11-27 | 1974-05-30 | Merck Patent Gmbh | Verfahren zur herstellung von pyrazolderivaten |
DE2513940A1 (de) * | 1975-03-29 | 1976-10-14 | Merck Patent Gmbh | Pharmazeutische zubereitung |
US4123529A (en) * | 1976-04-23 | 1978-10-31 | Lilly Industries Limited | Phenylpiperazine derivatives |
US4404382A (en) * | 1980-09-17 | 1983-09-13 | The Upjohn Company | Piperazinyl-substituted imidazoles |
US5254552A (en) * | 1988-05-24 | 1993-10-19 | American Home Products Corporation | Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity |
IL101722A (en) * | 1991-05-02 | 1996-05-14 | Wyeth John & Brother Ltd | History of piperazine, their preparation and pharmaceutical preparations containing them |
FR2682953B1 (fr) * | 1991-10-23 | 1995-04-21 | Inst Nat Sante Rech Med | Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique. |
SG65570A1 (en) * | 1992-02-25 | 1999-06-22 | Recordati Chem Pharm | Heterobicyclic compounds |
IT1254469B (it) * | 1992-02-25 | 1995-09-25 | Recordati Chem Pharm | Derivati benzopiranici e benzotiopiranici |
US5395835A (en) * | 1994-03-24 | 1995-03-07 | Warner-Lambert Company | Naphthalamides as central nervous system agents |
-
1994
- 1994-07-15 DE DE4425146A patent/DE4425146A1/de not_active Ceased
-
1995
- 1995-07-14 US US08/765,181 patent/US6090807A/en not_active Expired - Lifetime
- 1995-07-14 PT PT95926896T patent/PT771197E/pt unknown
- 1995-07-14 HU HU9700111A patent/HUT77608A/hu unknown
- 1995-07-14 KR KR1019970700265A patent/KR970704435A/ko active Search and Examination
- 1995-07-14 MX MX9700430A patent/MX9700430A/es not_active IP Right Cessation
- 1995-07-14 DE DE59510635T patent/DE59510635D1/de not_active Expired - Lifetime
- 1995-07-14 ES ES95926896T patent/ES2196072T3/es not_active Expired - Lifetime
- 1995-07-14 WO PCT/EP1995/002782 patent/WO1996002246A1/de active IP Right Grant
- 1995-07-14 NZ NZ290388A patent/NZ290388A/en unknown
- 1995-07-14 JP JP8504701A patent/JPH10502658A/ja not_active Ceased
- 1995-07-14 EP EP95926896A patent/EP0771197B1/de not_active Expired - Lifetime
- 1995-07-14 SI SI9520084A patent/SI9520084B/sl not_active IP Right Cessation
- 1995-07-14 CZ CZ199796A patent/CZ293126B6/cs not_active IP Right Cessation
- 1995-07-14 CN CN95194149A patent/CN1152870A/zh active Pending
- 1995-07-14 CN CNA2003101131172A patent/CN1534023A/zh active Pending
- 1995-07-14 KR KR10-2003-7012315A patent/KR100443850B1/ko not_active IP Right Cessation
- 1995-07-14 DK DK95926896T patent/DK0771197T3/da active
- 1995-07-14 AU AU31114/95A patent/AU704839B2/en not_active Ceased
- 1995-07-14 AT AT95926896T patent/ATE236629T1/de not_active IP Right Cessation
- 1995-07-14 CA CA002195242A patent/CA2195242A1/en not_active Abandoned
- 1995-07-14 BR BR9508296A patent/BR9508296A/pt active Search and Examination
-
1997
- 1997-01-06 BG BG101112A patent/BG63487B1/bg unknown
- 1997-01-14 FI FI970148A patent/FI970148A/fi not_active IP Right Cessation
- 1997-01-14 NO NO19970163A patent/NO311683B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
FI970148A0 (fi) | 1997-01-14 |
NO311683B1 (no) | 2002-01-07 |
DE59510635D1 (de) | 2003-05-15 |
CN1152870A (zh) | 1997-06-25 |
PT771197E (pt) | 2003-08-29 |
US6090807A (en) | 2000-07-18 |
AU3111495A (en) | 1996-02-16 |
SI9520084A (en) | 1997-08-31 |
FI970148A (fi) | 1997-01-14 |
DE4425146A1 (de) | 1996-01-18 |
AU704839B2 (en) | 1999-05-06 |
KR20040000412A (ko) | 2004-01-03 |
ATE236629T1 (de) | 2003-04-15 |
HUT77608A (hu) | 1998-06-29 |
BG101112A (en) | 1998-04-30 |
KR100443850B1 (ko) | 2004-08-11 |
EP0771197B1 (de) | 2003-04-09 |
SI9520084B (sl) | 2005-02-28 |
MX9700430A (es) | 1998-05-31 |
HU9700111D0 (en) | 1997-02-28 |
BR9508296A (pt) | 1998-05-19 |
KR970704435A (ko) | 1997-09-06 |
NO970163D0 (no) | 1997-01-14 |
NO970163L (no) | 1997-03-14 |
ES2196072T3 (es) | 2003-12-16 |
BG63487B1 (bg) | 2002-03-29 |
EP0771197A1 (de) | 1997-05-07 |
CZ9697A3 (en) | 1997-08-13 |
CA2195242A1 (en) | 1996-02-01 |
CZ293126B6 (cs) | 2004-02-18 |
JPH10502658A (ja) | 1998-03-10 |
DK0771197T3 (da) | 2003-06-23 |
NZ290388A (en) | 2001-04-27 |
WO1996002246A1 (de) | 1996-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1534023A (zh) | 作为多巴胺-d3配位体的杂环化合物 | |
CN1124269C (zh) | 取代的嘧啶化合物和其用途 | |
CN105073738B (zh) | 作为钠通道调节剂的喹啉及喹喔啉酰胺类 | |
CN1264840C (zh) | 8-甲氧基-(1,2,4)三唑并(1,5-a)吡啶衍生物及其作为腺苷受体配体的应用 | |
CN1068314C (zh) | 三唑化合物的及其作为多巴胺d3配位体的应用 | |
JP4387103B2 (ja) | セロトニン5ht−2レセプターのアゴニストまたはアンタゴニストとしてのピペラジニルピラジン化合物 | |
CN1255406C (zh) | 取代的2-芳基-3-(杂芳基)-咪唑并[1,2-a]嘧啶类化合物以及相关的药物组合物和方法 | |
US9815832B2 (en) | Azabenzimidazole compounds | |
CN1345319A (zh) | 与多巴胺d3受体具有亲和力的三唑化合物 | |
CN1434806A (zh) | 取代的咪唑神经肽yy5受体拮抗剂 | |
US10131669B2 (en) | Pyrazolopyrimidine compounds | |
TWI577681B (zh) | 咪唑并嗒化合物 | |
CN1152872A (zh) | 噻唑和噻二唑化合物作为d3多巴胺受体配位体的应用 | |
KR20100051625A (ko) | Cb1 길항제로서의 치환된 피페라진 | |
CN101356160A (zh) | 作为辣椒素受体拮抗剂的三取代的喹唑啉酮衍生物 | |
CN1933832A (zh) | 离子通道调节剂 | |
CN1206419A (zh) | 膦酸二酯衍生物 | |
CN114728170B (zh) | 对核受体具有活性的化合物 | |
CN1399631A (zh) | 新的乙内酰脲、乙内酰硫脲、嘧啶二酮和硫代嘧啶酮衍生物,制备方法和作为药物的用途 | |
CN1030753A (zh) | 制备新的取代n-(3-羟基-4-哌啶基)苯甲酰胺的方法 | |
CN1247584C (zh) | 1-[烷基]、1-[(杂芳基)烷基]和1-[(芳基)烷基]-7-吡啶基-咪唑并[1,2-a]嘧啶-5(1H)-酮衍生物 | |
WO2002102780A1 (fr) | Compose derive de tetrahydroquinoline et medicament contenant ledit compose comme principe actif | |
CN1564686A (zh) | 8-氨基-[1,2,4]三唑并[1,5-a]吡啶-6-甲酰胺 | |
CN104203928B (zh) | 三嗪酮化合物及t型钙通道阻滞剂 | |
CN1633421A (zh) | HPPAR-α受体的噁唑/噻唑衍生物活化剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |